2024
Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink
Denoble A, Vazquez-Benitez G, Sheth S, Ackerman-Banks C, DeSilva M, Zhu J, Daley M, Getahun D, Klein N, Vesco K, Irving S, Nelson J, Williams J, Hambidge S, Donahue J, Weintraub E, Kharbanda E, Lipkind H. Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstetrics And Gynecology 2024, 144: 215-222. PMID: 38843526, PMCID: PMC11250101, DOI: 10.1097/aog.0000000000005632.Peer-Reviewed Original ResearchVaccine Safety DatalinkAntepartum stillbirthVaccine Safety Datalink sitesLive birthsCOVID-19 vaccineVaccine dosePregnancy start dateRisk of severe morbidityRisk of stillbirthConditional logistic regressionCase-control studyVaccine manufacturersSingleton pregnanciesGestational ageFetal deathPostpartum visitMaternal ageIndex dateSevere morbidityDiagnostic codesPregnancyStillbirthPregnant peopleCOVID-19Logistic regressionObstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination
Vesco K, Denoble A, Lipkind H, Kharbanda E, DeSilva M, Daley M, Getahun D, Zerbo O, Naleway A, Jackson L, Williams J, Boyce T, Fuller C, Weintraub E, Vazquez-Benitez G. Obstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination. Obstetrics And Gynecology 2024, 143: 794-802. PMID: 38626447, PMCID: PMC11090513, DOI: 10.1097/aog.0000000000005583.Peer-Reviewed Original ResearchConceptsSmall-for-gestational ageMessenger RNA COVID-19 vaccineGestational diabetes mellitusRisk of adverse pregnancy outcomesAdverse pregnancy outcomesPreterm birthGestational hypertensionAdjusted hazard ratiosCOVID-19 vaccine dosesPregnancy outcomesCOVID-19 vaccineAssociated with small-for-gestational ageIncreased risk of adverse pregnancy outcomesVaccine doseRisk of preterm birthMessenger RNARetrospective cohort study of individualsMRNA COVID-19 vaccineWeeks of gestationRetrospective cohort studyHistory of COVID-19Cohort study of individualsVaccine Safety DatalinkSingleton pregnanciesUnexposed pregnancies
2019
Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth
DeNoble AE, Wynn CE, Weaver KE, Wheeler SM, Swamy GK. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth. American Journal Of Perinatology 2019, 37: 264-270. PMID: 30708392, DOI: 10.1055/s-0039-1678532.Peer-Reviewed Original ResearchConceptsSpontaneous preterm birthPrior term birthPrenatal care initiationEligible womenPreterm birthPrimary outcomeTerm birthsWeeks' gestationCare initiationHispanic ethnicityRecurrent spontaneous preterm birthSingleton spontaneous preterm birthPrior spontaneous preterm birthRecurrent preterm birthRetrospective cohort studyAcademic health systemStepwise logistic regressionSPTB rateCohort studyEligible subjectsSingleton pregnanciesClinical predictorsPoor adherenceMaternal ageCare barriers